

To view an archived recording of this presentation please click the following link:

https://youtu.be/AOSkY_9W5JA

Please scroll down this file to view a copy of the slides from the session.

Disclaimer

This document was created by its author and/or external organization. It has been published on the Public Health Ontario (PHO) website for public use as outlined in our Website Terms of Use. PHO is not the owner of this content. Any application or use of the information in this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.



CRISPR Diagnostics for Tackling Antimicrobial Resistance

Dr. Nikki Weckman



Disclosures

- I am a co-founder, shareholder and the Chief Technology Officer at 52 North Health
- **Disclaimer:** This presentation was created by its author. It will be published on the Public Health Ontario (PHO) website for public use as outlined in our Website Terms of Use. PHO is not the owner of this content. Any application or use of the information in this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

With thanks for funding, time, and expertise:




UNIVERSITY OF
TORONTO



EPIC
Emerging & Pandemic
Infections Consortium



UNIVERSITY OF TORONTO
FACULTY OF APPLIED SCIENCE & ENGINEERING
Centre for Global Engineering



NSERC
CRSNG



Keyser




Oxford
NANOPORE
Technologies


OPdA

Office of Postdoctoral Affairs



CANADA-UK
FOUNDATION

WYSS  INSTITUTE
for Biologically Inspired Engineering



**Wadsworth
Center**
NYSDOH 

**Collins
Lab**



By 2050 Antimicrobial Resistance could have:

- Caused up to **10 million deaths per year**
- Decreased productivity costing **US\$100 trillion**



O'Neill, J. "Antimicrobial resistance." Tackling a crisis for the health and wealth of nations (2014).

Diagnostics are critical for tackling antimicrobial resistance



Increase awareness and surveillance



Infection prevention and control



Reduce exposure to non-health antibiotics



Antibiotic stewardship

Requires surveillance, access, and diagnostics



Invest in vaccinations, new therapeutics,
diagnostics



**47% of the global
population has little to no
access to diagnostics**




Photo Credit [Kenn Chaplin](#)

We wish to acknowledge this land on which the University of Toronto operates. For thousands of years it has been the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work on this land.




Diverse sensor technologies are used in global healthcare


Decentralized & low resource settings



Emerging technologies for multi-use settings



Well-equipped centralized laboratories




Budd, J., Miller, B.S., **Weckman, N.E.** et al. Lateral flow test engineering and lessons learned from COVID-19. Nat Rev Bioeng 1, 13–31 (2023).

Wasswa, F.B., et al. MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities. Curr Clin Micro Rpt 9, 52–59 (2022).

Geyer, P.E., et al. "Proteomics reveals the effects of sustained weight loss on the human plasma proteome." Molecular systems biology 12.12 (2016): 901.

New diagnostics: what are the ideal characteristics?



■ REASSURED

- Real-time connectivity
- Ease of specimen collection
- Affordable
- Sensitive
- Specific
- User-friendly
- Rapid and robust
- Equipment free or simple
- Environmentally friendly
- Deliverable to users

Focus

Inter-related


■ Quantitative and Multiplexed

Land, Kevin J., et al. "REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes." *Nature microbiology* 4.1 (2019): 46-54.

Synthetic biology for sample to answer bioanalysis




Antifungal Resistance:
Candida Auris




STI Resistance:
N. gonorrhoea

Multiplexed and quantitative micro & nanoscale transducers



Nanopores



MEMS resonators

Commercial & User Centered Design




POC testing

Synthetic biology for sample to answer bioanalysis




Antifungal Resistance:
Candida Auris




STI Resistance:
N. gonorrhoea

Multiplexed and quantitative micro & nanoscale transducers



Nanopores




MEMS resonators

Commercial & User Centered Design




POC testing

Synthetic biology for diagnostics




Slomovic, Shimyn, Keith Pardee, and James J. Collins. "Synthetic biology devices for in vitro and in vivo diagnostics." *Proceedings of the National Academy of Sciences* 112.47 (2015): 14429-14435.



Further reading:

- Gootenberg et al. *Science*. 356.6336 (2017):438-442. doi: 10.1126/science.aam9321
- Chen et al. *Science*. 360.6387(2018):436-439. doi: 10.1126/science.aar6245

SHERLOCK Assay for Nucleic Acid Detection



Isothermal amplification improves sensitivity but limits quantification




Antifungal Resistance: *Candida Auris*

- Expanding detection of *Candida* species
- Rapidly screening for antifungal susceptibility
- Testing from samples (PHO)



Dr. Rob Kozak
Sunnybrook Research Institute
(EPIC, U of Toronto)




STI Infections: MDR *N. gonorrhoea*

- Rapid diagnostic to meet WHO and FIND TPP for STI screening
- Community engagement via Young African Refugees for Integral Development (YARID), Kampala, Uganda





Prof Carmen Logie
CRC in Global Health Equity
and Social Justice with
Marginalized Populations

SARS-CoV-2 and variants can be identified with SHERLOCK in saliva





Helena de Puig, ... **NE Weckman**...et al. "Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants." *Science Advances* 7.32 (2021): eabh2944.

Low-cost, modular, easy-to-use COVID variant detection



Helena de Puig, ... **NE Weckman**...et al. "Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants." *Science Advances* 7.32 (2021): eabh2944.


Sample to Result Infectious Disease Diagnostics






Karlikow, M., *et al.* Field validation of the performance of paper-based tests for the detection of the Zika and chikungunya viruses in serum samples. *Nat. Biomed. Eng* **6**, 246–256 (2022).

CARMEN-Cas13

(1) Amplify samples, add color codes and emulsify



Ackerman, C.M., Myhrvold, C., Thakku, S.G. *et al.* Massively multiplexed nucleic acid detection with Cas13. *Nature* **582**, 277–282 (2020).




Nouri, Reza, et al. "STAMP-Based Digital CRISPR-Cas13a for Amplification-Free Quantification of HIV-1 Plasma Viral Loads." *ACS nano* (2023): 512138.

Synthetic biology for sample to answer bioanalysis




Antifungal Resistance:
Candida Auris




STI Resistance:
N. gonorrhoea

Multiplexed and quantitative micro & nanoscale transducers



Nanopores




MEMS resonators


Commercial & User Centered Design






POC testing



Rapid DNA Identification using dCas9 Barcodes




Decorating DNA with dCas9 Barcodes in Nanopores










Multiplexing

λ : 1x T7: 1x
 $\lambda + T7 + E. coli$: 18x




How can we design and test better barcodes?






High throughput screening for detection of mutations



Information storage in DNA nanocarrier structures

- We can directly fingerprint DNA sequences for rapid identification using dCas9 barcodes
- We can rapidly screen DNA protein interactions like dCas9 sensitivity to mutations
- Highly scalable information storage: can we use this for multiplexed sensing of many biomarkers?





Translation of integrated sensor systems: Bench to Bedside

1. Co-creation with clinical experts, patients, including clinical pathway development
2. Automated result analysis and digital platforms for improved surveillance
3. Design for commercialization and sustainable manufacturing
4. Policy recommendations for decreased regulatory hurdles



Diagnostic devices never exist on their own



Human factors in healthcare IT: Management considerations and trends

Andre W. Kushniruk, MSc, PhD and Elizabeth M. Borycki, RN, PhD [View all authors and affiliations](#)

Volume 36, Issue 2 | <https://doi.org/10.1177/08404704221139219>

Usability problem	Example
Visibility problem	User (e.g. physician) is unable to see an alert presented by an electronic record user interface, as it is not prominently displayed ¹⁶
Understandability problem	User does not understand the onscreen instructions for patient treatment options ¹⁶
Unclear log on/off	User is not sure if they have logged off as the status of the system is not clearly indicated in the user interface ⁴
Documenting on the wrong patient record	User is unable to determine what patient they are documenting on due to multiple records open, and as a result inadvertently enters data into the wrong patient record ⁷
Navigational problem	User is unable to see how to navigate through a complex set of computer screens to get to a desired screen and section of the system ¹⁷

A comparative analysis of non-invasive prenatal testing in Ontario and Quebec: the role of governing style in health technology innovation & adoption

Lena Saleh, Gillian Parker, Michael Stevenson & Fiona A. Miller

BMC Health Services Research **23**, Article number: 231 (2023) | [Cite this article](#)

Budd, J., Miller, B.S., Weckman, N.E. *et al.* Lateral flow test engineering and lessons learned from COVID-19. *Nat Rev Bioeng* **1**, 13–31 (2023).


The pandemic has sparked a renaissance in the diagnostics field

- Decentralization of healthcare
- Diverse diagnostic use cases
- Equity in diagnostic access
- Sustainable production
- (Record levels of investment)


Useful further reading:

Fleming, Kenneth A., et al. "The Lancet Commission on diagnostics: Transforming access to diagnostics." *The Lancet* 398.10315 (2021): 1997-2050.

a COVID-19 self-testing




b COVID-19 tests in England



Budd, J., Miller, B.S., **Weckman, N.E.** *et al.* Lateral flow test engineering and lessons learned from COVID-19. *Nat Rev Bioeng* 1, 13–31 (2023).

Innovative sensor technologies will lay the foundation for sustainable and equitable global systems





“A correct diagnosis is three-fourths the remedy”
~Mahatma Gandhi

Have an idea of an unmet diagnostic need?
Want to chat about fun science?

Reach out: weckmanlab.com, Twitter: [@nikkiweckman](https://twitter.com/nikkiweckman)
nicole.weckman@utoronto.ca

